Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The remyelination phenomenon in multiple sclerosis].

Catherine Lubetzki1

  • 1Fédération de Neurologie et INSERM U-495, Groupe Hospitalier Pitié-Salpêtrière-47-83, Boulevard de l'Hôpital-75651 Paris.

Bulletin De L'Academie Nationale De Medecine
|October 15, 2003
PubMed
Summary

Multiple sclerosis treatments reduce inflammation but fail to restore myelin. Understanding why remyelination fails is key to developing new therapies for this central nervous system disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnetoencephalography biomarkers for assessing myelin content and neuronal function in acute optic neuritis.

Brain communications·2026
Same author

Neuronal Activity Promotes Node-Like Cluster Assembly Prior to Myelination and Remyelination in the Central Nervous System.

Glia·2026
Same author

Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder.

Neurology·2025
Same author

Frequent detection of IFN-gamma -producing memory effector and effector T cells in patients with progressive multifocal leukoencephalopathy.

Frontiers in immunology·2024
Same author

Cerebellar encephalitis and peripheral neuropathy with an atypical clinical and neuroimaging signature following Covid-19 vaccine: a report of two cases.

Journal of neurology·2024
Same author

Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies.

Multiple sclerosis and related disorders·2024

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Context:

  • Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease affecting the central nervous system (CNS).
  • Current treatments, including immunomodulators and immunosuppressants, primarily target CNS inflammation.
  • These therapies offer partial effectiveness and do not fully halt disease progression or repair myelin damage.

Purpose:

  • To investigate the multifactorial reasons behind the failure of remyelination in progressive multiple sclerosis.
  • To identify key oligodendroglial, axonal, and environmental factors contributing to the repair deficit.
  • To establish a foundation for developing novel therapeutic strategies aimed at enhancing remyelination.

Summary:

  • Multiple sclerosis involves CNS inflammation and myelin loss, with insufficient remyelination as the disease advances.

Related Experiment Videos

  • The failure in myelin repair is attributed to complex interactions involving oligodendroglial cells, axons, and the surrounding microenvironment.
  • Identifying these specific barriers is essential for understanding the disease's pathology.

    • Impact:

    • This research is crucial for advancing the understanding of multiple sclerosis pathogenesis.
    • Findings will guide the development of innovative treatments focused on promoting remyelination in MS patients.
    • Improved remyelination strategies could significantly enhance functional recovery and quality of life for individuals with MS.